Navigation Links
VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
Date:5/23/2011

promising and indicate that VivaGel(R) is a potentially useful alternative acute treatment for BV that is different from the systemic and topical antibiotic agents that are the current mainstay of treatment."

The study was a double-blind, randomized, placebo controlled, dose ranging Phase 2 study and was conducted at sites in the US under an Investigational New Drug (IND) application with the US FDA.  The study enrolled 132 women who were randomized to receive VivaGel(R) (0.5%, 1% or 3% SPL7013), or placebo.  The incidence of adverse events, including genitourinary adverse events, was similar across all placebo gel and VivaGel(R) groups. No severe (grade 3) adverse events were observed in the VivaGel(R) groups. Two severe adverse events were observed in the placebo.

Additional details and results from the study are provided in the Appendix to this announcement.

Addressable global market for BV treatment and prevention potentially exceeds $1B

The global market for topical BV treatments alone is estimated at approximately US$350M. Starpharma's modeling suggests the addressable global market for prevention of recurrence of BV is potentially in excess of $1 billion, due to the long term usage associated with such a product.

Trial results support new patent filing which extends VivaGel(R) protection to at least 2032
On the basis of the data from this phase 2 study, Starpharma has filed a new patent application relating to BV that will, once granted, expand and extend patent protection for VivaGel(R) to at least 2032.

Planning underway for Phase 3 trials for VivaGel(R) for BV treatment
Based on the results of this phase 2 study, Starpharma will undertake further discussions with regulatory authorities, with a view to initiating phase 3 registration trials of VivaGel(R) for the treatment of BV in late 2011 or early 2012.

BV prevention trial of VivaGel(R) to commence Q3 2011
As previously announced Sta
'/>"/>

SOURCE Starpharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, today announced it has ... the U.S. Food and Drug Administration (FDA) of 2015, ... now pending at the FDA to twenty-nine. ... Company, commented, "We believe our current pipeline of twenty-nine ...
(Date:9/4/2015)... Sep. 04, 2015 Research and ... "Investigation Report on China,s Sodium Ibandronate Market, 2010-2019" ... in the clinic under the trade name of Bondronat in ... in 1996, sodium ibandronate was approved by the FDA ... osteoporosis under the trade name of Boniva. However, since drug ...
(Date:9/4/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a ... new cancer therapies, today announced its financial results for ... an overview of recent Company highlights and expected near-term ... a business update conference call and live webcast for ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces Seventh ANDA Submission Of 2015 2Investigation Report on China's Sodium Ibandronate Market 2010-2019 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8
... ... 7 , Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) and ... of positive data from a phase 1 study of TRU-016 in ... 2009 American Society of Hematology (ASH) Annual Meeting. TRU-016 is a ...
... , HOBOKEN, N.J., Dec. 7 ... the U.S. Food and Drug Administration has approved ... in patients with all types of von Willebrand disease (VWD). Wilate® ... Factor VIII Concentrate (Human) that demonstrated efficacy for all types of ...
Cached Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5
(Date:9/4/2015)... ... September 04, 2015 , ... Georgia ... is launching a charity effort to provide for the family of Grace, a ... enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – the inability to ...
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of mind ... home is quite common. Mold can grow anywhere - on carpet, clothing, food, paper, ... for excessive moisture and water in the home is key to preventing mold growth, ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a fresh ... its only mission and research focus: Water Life Science®. In the current warming ... evaporation is becoming dangerously accelerated. As a result of the global fresh water, ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 ... up with victory in the men’s 400 meters final, with an impressive 44.89 seconds ... Championships in San Jose, Costa Rica in August 2015. The 44.64 time is a ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... medical assistance company today announced that it has entered into a multi-year agreement ... signed an agreement to bridge the link between American healthcare, Jamaican healthcare and ...
Breaking Medicine News(10 mins):Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6
... ... quality of life. , ... Hamilton, AL (PRWEB) Jeanne Crace, 70, who has five daughters, seven grandchildren ... , , , , ,Parkinson,s Disease remains a mystery of medical science. For reason,s ...
... ... researchers to quickly and effectively use this invaluable next-generation resource. , ... Seattle, WA (PRWEB) August 10, 2009 ... iHOP, or Information Hyperlinked Over Proteins. iHOP is a sophisticated, next generation ...
... ... facelift using ultrasound. 30 minutes to a tighter skin, a more lifted and contoured ... ... 9, 2009 -- Ulthera is set to revolutionalize the arena of non-surgical facelift. This ...
... these helpful tips , SATURDAY, Aug. 8 (HealthDay News) -- ... helps if parents and children are well-prepared, advises the American ... source of stress for a person of any age, but ... of sensitivity is added," ASA President Dr. Roger A. Moore ...
... BEIJING, Aug. 7 /PRNewswire-Asia-FirstCall/ -- China ... ), a leading China-based medical device,company that develops, ... the appointment of PricewaterhouseCoopers ("PwC") as,the Company,s independent ... independent auditors, KPMG. , ...
... , PROVO, Utah, Aug. 7 Nu Skin Enterprises, ... directors has declared a quarterly dividend of $0.115 per share which ... on Aug. 28, 2009. , , The ... been demonstrating its tradition of innovation through its comprehensive anti-aging product ...
Cached Medicine News:Health News:Exploring Newly Found Freedom with the GaitAid for Parkinson's Disease 2Health News:Exploring Newly Found Freedom with the GaitAid for Parkinson's Disease 3Health News:New Online Tutorial for iHOP from OpenHelix 2Health News:New Online Tutorial for iHOP from OpenHelix 3Health News:The Sloane Clinic pioneers Ultherapy in Singapore 2Health News:The Sloane Clinic pioneers Ultherapy in Singapore 3Health News:Good Planning Paves Way for Kid's Operation 2Health News:China Medical Technologies Announces Change of Independent Auditors 2
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Conversion Kits For Modular Incubator Chamber...
Medicine Products: